Project Grant R01HL177430
Award Date
5/1/25
Completion Date
1/31/29
Dollars Obligated
$542K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, awarded a $1,022,908 Project Grant to The DNA Medicine Institute, Inc. to develop a rapid, 5-minute point-of-care test for measuring anti-Factor Xa activity and hemoglobin levels. The goal is to create a diagnostic tool that can guide emergency management for patients on direct oral anticoagulants, enabling quicker delivery of life-saving interventions. The...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded Levisonics Inc. a $299,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a point-of-care coagulation analyzer for hemophilia patients. The project aims to create a prototype of Levisonics' acoustic tweezing spectroscopy (ATS) technology, which can provide a comprehensive coagulation profile from a single drop of whole blood. This innovative...
The federal Project Grant award R21HL172497, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, supports the engineering of a lab-on-a-particle platform to measure platelet function. The $225,600 award to the University of Colorado-Denver aims to design elastic hydrogel microparticles that can assess platelet adhesion, activation, aggregation, and contraction through high-throughput kinetic and equilibrium assays....
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $483,852 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a high-throughput platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to enable the optimization of emerging sickle cell disease...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $400,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The purpose of this 1-year project is to develop an innovative analytical testing device for the precise quantitative characterization of lipoprotein particles in blood. Lipoproteins are important indicators of cardiovascular disease risk, as certain...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Hematherix LLC, a woman-owned small business in California. The award supports the development of SuperFVa, an engineered variant of activated coagulation cofactor Factor V, as a targeted therapy to prevent and correct acute traumatic coagulopathy (ATC). ATC is characterized by diminished levels of key clotting factors, leading to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $437,461 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to 3DT Holdings, LLC, a minority-owned biomedical engineering company in San Diego, California. The grant will fund the development and validation of a novel stabilization catheter for His pacing lead implantation, a critical procedure for treating heart failure patients with left bundle branch block. The project aims to refine the design of a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $693,423 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Baylor College of Medicine. The grant's objective is to develop and validate a microfluidic device capable of purifying platelets while preserving their hemostatic function, with the goal of providing safer platelet transfusions for pediatric and neonatal patients. The 4-year project (5/1/2025 - 2/28/2029) will optimize the efficiency of the...
This federal Project Grant award of $552,413 was provided by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to investigate the use of short inhibitory RNAs (siRNAs) to selectively knockdown gene expression in megakaryocytes and platelets, with the goals of developing novel antithrombotic therapies and enhancing understanding of platelet molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA 93.837 program, provides $306,656 to Bioparin, LLC to develop biotechnological approaches for expeditious production of synthetic heparin-like anticoagulants. The project aims to establish engineered microbial "cellular factories" capable of manufacturing unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) through modern fermentation...